Open access
Sep 2026
Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study
Although immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain. This real‐world study assessed the efficacy and...
Yu-Xia Wang, Yun-Feng Tong, Yang Pan et al.
· Cancer Medicine · 0 citations